Benign Prostatic Hyperplasia Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Benign Prostatic Hyperplasia Market is segmented by Drug Type (Alpha-Blockers, 5- Alpha-Reductase Inhibitors (5-Aris), Alpha-Adrenergic Blockers, Phosphodiesterase-5 Enzyme Inhibitors, and Other Drug Types), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Benign Prostatic Hyperplasia Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Benign Prostatic Hyperplasia Market Size

Benign Prostatic Hyperplasia Market Size
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 8.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Benign Prostatic Hyperplasia Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Benign Prostatic Hyperplasia Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Benign Prostatic Hyperplasia Market Analysis

The Benign Prostatic Hyperplasia Market is expected to register a CAGR of 8.5% during the forecast period.

According to the Union for International Cancer Control (UICC) in May 2020, there was a significant decrease in disease diagnostic rates in the United States during the COVID-19 pandemic. This had a significant impact on the market growth. However, such hindering impact on growth is anticipated to persist for a short duration. Moreover, according to the study titled 'Impact of the COVID-19 outbreak on prostate care in the Netherlands', published in the Cancer Treatment and Research Communications in January 2022, during the first COVID-19 wave, there was a 17% decrease in prostate cancer diagnoses. The reduction was most noticeable among the elderly and those with low-risk localized prostate conditions such as Benign Prostate Hyperplasia.

Benign prostatic hyperplasia (BPH) is being accepted as a growing health problem among elderly men. As per the 2022 data published by World Population Review, the average age of men is highest in Monaco i.e., 52 years as of 2022. The data suggests that the old men population is believed to increase rapidly over the coming years. With the rising population of aged men, the degree of the problem is projected to rise multifold over the next few years.

The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to prostate cancer. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. By 2050, 80% of the world's elderly will live in low and middle-income countries. The population is aging at a much faster rate than in the past. Every country faces significant challenges in ensuring that its health and social systems are prepared to take advantage of this demographic shift. According to the World Health Organization, in May 2020, by 2030, one out of every six people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Benign prostate hyperplasia (BOH) is majorly associated with the age of a person and as the age increases, the chances of BPH increases. Hence, with a rise in geriatric population, the market studied is expected to witness strong growth in coming years.

Benign Prostatic Hyperplasia Industry Overview

Key players that are expected to be dominant in Benign Prostatic Hyperplasia market are Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., and Astellas Pharma Inc. The companies are implementing certain strategic initiatives, such as a merger, new product launch, acquisition, and partnerships that help them in strengthening their market position.

Benign Prostatic Hyperplasia Market Leaders

  1. Allergan PLC

  2. Eli Lilly and Company

  3. Merck & Co., Inc.

  4. Boehringer Ingelheim

  5. Astellas Pharma Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., and Astellas Pharma Inc.
Need More Details on Market Players and Competiters?
Download PDF

Benign Prostatic Hyperplasia Market News

  • In June 2022, Astellas Pharma Inc. and GO Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas) and GO have entered into a strategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.
  • In December 2021, Veru announced FDA Approval of ENTADFI, a new treatment for Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population
    • 4.2.2 Growing Technological Advancements in Personalized Medicines
  • 4.3 Market Restraints
    • 4.3.1 Rising Preference Toward Minimally Invasive Surgeries
    • 4.3.2 Non-adherence of Patients to Pharmacological Therapy
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 Alpha-Blockers
    • 5.1.2 5- Alpha-Reductase Inhibitors (5-Aris)
    • 5.1.3 Alpha-Adrenergic Blockers
    • 5.1.4 Phosphodiesterase-5 Enzyme Inhibitors
    • 5.1.5 Other Drug Types
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 Boehringer Ingelheim
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Nymox Pharmaceutical Corporation
    • 6.1.7 Pfizer Inc
    • 6.1.8 Sanofi
    • 6.1.9 Sophiris Bio Corp
    • 6.1.10 Teva Pharmaceutical Industries Limited
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Benign Prostatic Hyperplasia Industry Segmentation

As per the scope of the report, benign prostatic hyperplasia is a medical condition involving enlargement of the prostate gland and it is highly prevalent in males. It is a non-cancerous growth of the prostate gland originating from the uncontrolled expansion of prostate cells. The Benign Prostatic Hyperplasia Market is segmented by Drug Type (Alpha-Blockers, 5- Alpha-Reductase Inhibitors (5-Aris), Alpha-Adrenergic Blockers, Phosphodiesterase-5 Enzyme Inhibitors, and Other Drug Types), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments. 

By Drug Type Alpha-Blockers
5- Alpha-Reductase Inhibitors (5-Aris)
Alpha-Adrenergic Blockers
Phosphodiesterase-5 Enzyme Inhibitors
Other Drug Types
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Benign Prostatic Hyperplasia Market Research FAQs

What is the current Benign Prostatic Hyperplasia Market size?

The Benign Prostatic Hyperplasia Market is projected to register a CAGR of 8.5% during the forecast period (2025-2030)

Who are the key players in Benign Prostatic Hyperplasia Market?

Allergan PLC, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim and Astellas Pharma Inc. are the major companies operating in the Benign Prostatic Hyperplasia Market.

Which is the fastest growing region in Benign Prostatic Hyperplasia Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Benign Prostatic Hyperplasia Market?

In 2025, the North America accounts for the largest market share in Benign Prostatic Hyperplasia Market.

What years does this Benign Prostatic Hyperplasia Market cover?

The report covers the Benign Prostatic Hyperplasia Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Benign Prostatic Hyperplasia Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Benign Prostatic Hyperplasia Industry Report

Statistics for the 2025 Benign Prostatic Hyperplasia market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Benign Prostatic Hyperplasia analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.